Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bendamustine
Drug ID BADD_D00230
Description Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Indications and Usage Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Marketing Status approved; investigational
ATC Code L01AA09
DrugBank ID DB06769
KEGG ID D07501
MeSH ID D000069461
PubChem ID 65628
TTD Drug ID D01CYA
NDC Product Code 68554-0050
UNII 9266D9P3PQ
Synonyms Bendamustine Hydrochloride | Hydrochloride, Bendamustine | Bendamustine | Bendamustin | Cytostasan | IMET 3393 | Ribomustin | Treanda | Zimet 3393
Chemical Information
Molecular Formula C16H21Cl2N3O2
CAS Registry Number 16506-27-7
SMILES CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Metabolic encephalopathy17.13.01.001; 14.11.01.0130.000112%Not Available
Metastasis16.22.01.001--Not Available
Infusion site extravasation12.07.05.008; 08.02.05.0070.001959%
Chronic kidney disease20.01.03.0170.000112%
Infusion site irritation12.07.05.011; 08.02.05.0100.002093%Not Available
Bone marrow failure01.03.03.0050.001063%
Cytopenia01.03.03.0120.000616%Not Available
Oral disorder07.05.01.0050.000358%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.000470%
Acute kidney injury20.01.03.0160.001119%
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 10.01.01.021; 23.03.05.0050.000280%Not Available
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.005--Not Available
Autoimmune haemolytic anaemia10.04.01.005; 01.06.01.0040.000336%Not Available
Candida infection11.03.03.021--
Multiple organ dysfunction syndrome08.01.03.0570.000336%
Adenocarcinoma of colon16.13.01.010; 07.21.01.0080.000112%Not Available
Chronic lymphocytic leukaemia recurrent01.10.06.003; 16.01.06.0030.000280%Not Available
Diffuse large B-cell lymphoma recurrent16.28.02.002; 01.15.02.0020.000336%Not Available
Diffuse large B-cell lymphoma refractory16.28.02.003; 01.15.02.0030.000168%Not Available
Non-Hodgkin's lymphoma recurrent16.35.01.002; 01.17.01.0020.000112%Not Available
Venous stenosis24.04.02.0290.000381%Not Available
Secondary immunodeficiency10.03.03.0090.000112%Not Available
Peripheral artery occlusion24.04.03.0220.000112%Not Available
Richter's syndrome01.15.02.005; 16.28.02.0050.000168%Not Available
Lymphoma transformation16.20.01.006; 01.12.01.0060.000112%Not Available
Stress urinary incontinence20.02.02.0220.000761%Not Available
Respiratory tract inflammation22.02.07.0150.000246%Not Available
Bone marrow infiltration01.05.01.0180.000168%Not Available
Blastic plasmacytoid dendritic cell neoplasia23.07.04.021; 16.20.01.004; 01.12.01.0040.000112%Not Available
Autoimmune colitis07.08.01.017; 10.04.04.0100.000112%Not Available
The 11th Page    First    Pre   11 12    Next   Last    Total 12 Pages